238 related articles for article (PubMed ID: 31281496)
21. G9a stimulates CRC growth by inducing p53 Lys373 dimethylation-dependent activation of
Zhang J; Wang Y; Shen Y; He P; Ding J; Chen Y
Theranostics; 2018; 8(10):2884-2895. PubMed ID: 29774081
[No Abstract] [Full Text] [Related]
22. Small molecule inhibition of polo-like kinase 1 by volasertib (BI 6727) causes significant melanoma growth delay and regression in vivo.
Cholewa BD; Ndiaye MA; Huang W; Liu X; Ahmad N
Cancer Lett; 2017 Jan; 385():179-187. PubMed ID: 27793694
[TBL] [Abstract][Full Text] [Related]
23. Cotargeting Polo-Like Kinase 1 and the Wnt/β-Catenin Signaling Pathway in Castration-Resistant Prostate Cancer.
Li J; Karki A; Hodges KB; Ahmad N; Zoubeidi A; Strebhardt K; Ratliff TL; Konieczny SF; Liu X
Mol Cell Biol; 2015 Dec; 35(24):4185-98. PubMed ID: 26438599
[TBL] [Abstract][Full Text] [Related]
24. High expression of polo-like kinase 1 is associated with the metastasis and recurrence in urothelial carcinoma of bladder.
Zhang Z; Zhang G; Kong C
Urol Oncol; 2013 Oct; 31(7):1222-30. PubMed ID: 22192978
[TBL] [Abstract][Full Text] [Related]
25. FBXO32 suppresses breast cancer tumorigenesis through targeting KLF4 to proteasomal degradation.
Zhou H; Liu Y; Zhu R; Ding F; Wan Y; Li Y; Liu Z
Oncogene; 2017 Jun; 36(23):3312-3321. PubMed ID: 28068319
[TBL] [Abstract][Full Text] [Related]
26. PLK1 stabilizes a MYC-dependent kinase network in aggressive B cell lymphomas.
Ren Y; Bi C; Zhao X; Lwin T; Wang C; Yuan J; Silva AS; Shah BD; Fang B; Li T; Koomen JM; Jiang H; Chavez JC; Pham LV; Sudalagunta PR; Wan L; Wang X; Dalton WS; Moscinski LC; Shain KH; Vose J; Cleveland JL; Sotomayor EM; Fu K; Tao J
J Clin Invest; 2018 Dec; 128(12):5517-5530. PubMed ID: 30260324
[TBL] [Abstract][Full Text] [Related]
27. Polo-like-kinase 1 is a proviral host factor for hepatitis B virus replication.
Diab A; Foca A; Fusil F; Lahlali T; Jalaguier P; Amirache F; N'Guyen L; Isorce N; Cosset FL; Zoulim F; Andrisani O; Durantel D
Hepatology; 2017 Dec; 66(6):1750-1765. PubMed ID: 28445592
[TBL] [Abstract][Full Text] [Related]
28. Regulation of cell apoptosis and proliferation in pancreatic cancer through PI3K/Akt pathway via Polo-like kinase 1.
Mao Y; Xi L; Li Q; Cai Z; Lai Y; Zhang X; Yu C
Oncol Rep; 2016 Jul; 36(1):49-56. PubMed ID: 27220401
[TBL] [Abstract][Full Text] [Related]
29. LPLUNC1 inhibits nasopharyngeal carcinoma cell growth via down-regulation of the MAP kinase and cyclin D1/E2F pathways.
Yang Y; Liao Q; Wei F; Li X; Zhang W; Fan S; Shi L; Li X; Gong Z; Ma J; Zhou M; Xiang J; Peng S; Xiang B; Deng H; Yang Y; Li Y; Xiong W; Zeng Z; Li G
PLoS One; 2013; 8(5):e62869. PubMed ID: 23650533
[TBL] [Abstract][Full Text] [Related]
30. Dual targeting of Polo-like kinase 1 and baculoviral inhibitor of apoptosis repeat-containing 5 in TP53-mutated hepatocellular carcinoma.
Li Y; Zhao ZG; Luo Y; Cui H; Wang HY; Jia YF; Gao YT
World J Gastroenterol; 2020 Aug; 26(32):4786-4801. PubMed ID: 32921957
[TBL] [Abstract][Full Text] [Related]
31. Proliferation state and polo-like kinase1 dependence of tumorigenic colon cancer cells.
Francescangeli F; Patrizii M; Signore M; Federici G; Di Franco S; Pagliuca A; Baiocchi M; Biffoni M; Ricci Vitiani L; Todaro M; De Maria R; Zeuner A
Stem Cells; 2012 Sep; 30(9):1819-30. PubMed ID: 22753241
[TBL] [Abstract][Full Text] [Related]
32. WNT5A promotes stemness characteristics in nasopharyngeal carcinoma cells leading to metastasis and tumorigenesis.
Qin L; Yin YT; Zheng FJ; Peng LX; Yang CF; Bao YN; Liang YY; Li XJ; Xiang YQ; Sun R; Li AH; Zou RH; Pei XQ; Huang BJ; Kang TB; Liao DF; Zeng YX; Williams BO; Qian CN
Oncotarget; 2015 Apr; 6(12):10239-52. PubMed ID: 25823923
[TBL] [Abstract][Full Text] [Related]
33. Elevated FBXO45 promotes liver tumorigenesis through enhancing IGF2BP1 ubiquitination and subsequent PLK1 upregulation.
Lin XT; Yu HQ; Fang L; Tan Y; Liu ZY; Wu D; Zhang J; Xiong HJ; Xie CM
Elife; 2021 Nov; 10():. PubMed ID: 34779401
[TBL] [Abstract][Full Text] [Related]
34. LASP1 promotes nasopharyngeal carcinoma progression through negatively regulation of the tumor suppressor PTEN.
Gao Q; Tang L; Wu L; Li K; Wang H; Li W; Wu J; Li M; Wang S; Zhao L
Cell Death Dis; 2018 Mar; 9(3):393. PubMed ID: 29531214
[TBL] [Abstract][Full Text] [Related]
35. [Polo like kinase 1 expression and prognostic value in gastric carcinomas].
Lan B; Liu BY; Chen XH; Qu Y; Zhang XQ; Cai Q; Zhu ZG
Zhonghua Wei Chang Wai Ke Za Zhi; 2007 Jan; 10(1):70-2. PubMed ID: 17253180
[TBL] [Abstract][Full Text] [Related]
36. Cancer Osaka thyroid (Cot) phosphorylates Polo-like kinase (PLK1) at Ser137 but not at Thr210.
Wu B; Jiang P; Mu Y; Wilmouth RC
Biol Chem; 2009 Dec; 390(12):1271-7. PubMed ID: 19804365
[TBL] [Abstract][Full Text] [Related]
37. Blockage of SSRP1/Ets-1/Pim-3 signalling enhances chemosensitivity of nasopharyngeal carcinoma to docetaxel in vitro.
Ai J; Li W; Zeng R; Xie Z; Liu H; Hou M; Tan G
Biomed Pharmacother; 2016 Oct; 83():1022-1031. PubMed ID: 27525970
[TBL] [Abstract][Full Text] [Related]
38. Identification of beta-catenin as a novel substrate of Polo-like kinase 1.
Arai T; Haze K; Iimura-Morita Y; Machida T; Iida M; Tanaka K; Komatani H
Cell Cycle; 2008 Nov; 7(22):3556-63. PubMed ID: 19001871
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of Polo-Like Kinase 1 by BI2536 Reverses the Multidrug Resistance of Human Hepatoma Cells In Vitro and In Vivo.
Li HY; Luo F; Li XY; Fu XF; He JF; Tian YZ; Zhu JJ; Chu XY; Zhao HL
Anticancer Agents Med Chem; 2019; 19(6):740-749. PubMed ID: 30836927
[TBL] [Abstract][Full Text] [Related]
40. Phosphorylation of TCTP as a marker for polo-like kinase-1 activity in vivo.
Cucchi U; Gianellini LM; De Ponti A; Sola F; Alzani R; Patton V; Pezzoni A; Troiani S; Saccardo MB; Rizzi S; Giorgini ML; Cappella P; Beria I; Valsasina B
Anticancer Res; 2010 Dec; 30(12):4973-85. PubMed ID: 21187478
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
